AstraZeneca announced positive Phase III trial results for Breztri Aerosphere in uncontrolled asthma patients, showing statistically significant improvements over dual-combination therapies. Deutsche Bank maintained a Sell rating with a £115 price target.
Phase III KALOS and LOGOS trial results published in The Lancet Respiratory Medicine show Breztri Aerosphere improved lung function and reduced severe asthma exacerbations compared to dual-combination therapies in patients with uncontrolled asthma.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT06753214 |
Telemedicine Education for Caregivers and Asthma Control in Children |
RECRUITING | NA |
| NCT06681545 |
Exploring the Lived Experience of Young Adults With Severe Asthma |
RECRUITING | |
| NCT06521229 |
Clinical& Demographic Profiles of patIents With unControllEd Asthma in Russia: Multi-center oBsErvational ReGistry Study |
RECRUITING | |
| NCT06448585 |
Dietary Supplement (Beta-Glucans) in Allergic Patients Undergoing Subcutaneous Immunotherapy. |
COMPLETED | PHASE4 |
| NCT06029595 |
Efficacy and Safety of Tanimilast in Asthmatics uNcontrolled on ICS-containinG backgrOund Maintenance Therapy |
TERMINATED | PHASE2 |
| NCT04865575 |
Systems Pharmacology Approach to Uncontrolled Pediatric Asthma |
COMPLETED | |
| NCT03978936 |
Medication Adherence With Telehealthcare Medication Therapy Management |
COMPLETED | NA |
| NCT02906761 |
Aspirin for Uncontrolled Asthma |
COMPLETED | PHASE3 |
| NCT02768623 |
Evaluation of a Community Pharmacist Managed Asthma Consultation Service |
COMPLETED | NA |
| NCT02194699 |
A Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults and Adolescents With Uncontrolled Asthma |
COMPLETED | PHASE3 |
